Roger Estevez, MD
Internal Medicine · Las Vegas, NVNPI 1871734178
Payments from drug & device makers
Across 767 payments — averaging $4780.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.4M
- AstraZeneca$630K
- Alnylam Pharmaceuticals Inc.$356K
- Boehringer Ingelheim International GmbH$230K
- Eli Lilly$206K
- AbbVie$189K
- plus $622K from 27 others
Across 11 payments — averaging $3066.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$34K
What the payments were for
- Consulting fees$1,2006%
- Speaking & faculty fees$4,56424%
- Travel & lodging$4,97926%
- Food & beverage$8,64945%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 33 | $1,432,917 |
| AstraZeneca | 55 | $630,235 |
| Alnylam Pharmaceuticals Inc. | 54 | $356,232 |
| Boehringer Ingelheim International GmbH | 125 | $230,195 |
| Eli Lilly | 5 | $206,039 |
| AbbVie(2 entities) | 130 | $189,333 |
| Vanda Pharmaceuticals Inc. | 33 | $186,850 |
| Ironwood Pharmaceuticals, Inc | 15 | $119,677 |
| Akcea Therapeutics, Inc. | 5 | $98,115 |
| Ionis Pharmaceuticals, Inc. | 9 | $74,089 |
| Teva Pharmaceuticals USA, Inc. | 126 | $73,146 |
| Ortho-clinical Diagnostics, Inc. | 3 | $32,634 |
| Pfizer | 7 | $19,065 |
| Sanofi US Services Inc. | 1 | $9,550 |
| Merck | 23 | $4,130 |
| Biohaven Pharmaceuticals, Inc. | 12 | $1,658 |
| Novo Nordisk | 36 | $899 |
| Johnson & Johnson | 19 | $494 |
| Amarin Pharma, Inc. | 3 | $266 |
| Sanofi-aventis U.S. LLC | 14 | $231 |
| Lilly USA, LLC | 10 | $212 |
| Axsome Therapeutics, Inc. | 1 | $150 |
| Amgen | 9 | $134 |
| Bayer | 7 | $129 |
| Mannkind Corporation | 8 | $126 |
| Boehringer Ingelheim | 5 | $95 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $93 |
| Dexcom, Inc. | 6 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| BD | 1 | $33 |
| Abbott | 1 | $27 |
| Astellas Pharma US Inc | 1 | $22 |
| Lupin Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,666,935 in reported general payments places this provider in the 95th percentile of 1,071 internal medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 106 | $101,932 |
| FarxigaDapagliflozin Propanediol | 70 | $91,288 |
| EliquisApixaban | 76 | $65,709 |
| OzempicSemaglutide | 45 | $50,781 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 67 | $43,392 |
| LinzessLinaclotide | 35 | $41,802 |
| XareltoRivaroxaban | 43 | $41,420 |
| JanuviaSitagliptin Phosphate | 29 | $34,113 |
| TrulicityDulaglutide | 21 | $29,299 |
| RybelsusSemaglutide | 14 | $28,501 |
| MounjaroTirzepatide | 15 | $20,425 |
| KerendiaFinerenone | 15 | $19,988 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $18,131 |
| Diclofenac Sodium | 236 | $14,937 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $14,542 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $630,235 | $138,754149 claims |
| Boehringer IngelheimJardiance, Tradjenta | $95 | $116,047120 claims |
| Novo NordiskOzempic, Rybelsus | $899 | $79,28259 claims |
| PfizerEliquis | $19,065 | $65,70976 claims |
| MerckJanuvia, Janumet | $4,130 | $52,24446 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $212 | $49,72436 claims |
| AbbVieLinzess | $189,333 | $41,80235 claims |
| Johnson & JohnsonXarelto | $494 | $41,42043 claims |
| BayerKerendia | $129 | $19,98815 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $231 | $9,50414 claims |
| NovartisEntresto | $1,432,917 | $8,98913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Las Vegas
- Darin BrimhallLas Vegas$39.7M
- Alton WaltersLas Vegas$8.9M
- Michael JacobsLas Vegas$8.1M
- Nirupa PaulrajLas Vegas$5.8M
- Atoya AdamsLas Vegas$5.4M
- Syed PervaizLas Vegas$3.1M
- Vrijendra HoonLas Vegas$1.8M
- Robby Ann QuintosLas Vegas$1.4M
- Kent SwaineLas Vegas$1.2M
- Vishweshwar RangaLas Vegas$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.